Related Experiment Video

Updated: Mar 19, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Protein Delivery of Thymidylate Kinase Mediated by Tumor-Specific Antibody-Precoated Microvesicles

Mohammad Mohammadzadeh-Vardin1, Hamdollah Panahpour2, Mohammad Ghasem Golmohammadi1

  • 1Research Laboratory for Embryology and Stem Cells, Department of Anatomical Sciences and Pathology, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.

Critical Reviews in Eukaryotic Gene Expression
|June 10, 2016
PubMed

Insights

This study explores using antibody-coated microvesicles to deliver a suicide protein to prostate cancer cells. This targeted approach aims to enhance cancer cell death when treated with azidothymidine (AZT).

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Molecular targeted therapy offers a novel approach to cancer treatment by interfering with specific molecules driving cancer growth.
  • Prostate cancer remains a significant cause of cancer-related mortality in men, necessitating innovative therapeutic strategies.
  • Current research explores various targeted therapies, including monoclonal antibodies and suicide gene therapy, for prostate cancer treatment.

Purpose of the Study:

  • To investigate the potential of antibody-coated microvesicles as a delivery system for suicide proteins in prostate cancer.
  • To evaluate the efficacy of delivering thymidylate kinase (a suicide protein) to prostate cancer cells via microvesicles.
  • To determine if this targeted delivery potentiates prostate cancer cell death upon subsequent azidothymidine (AZT) treatment.

Main Methods:

  • Development of antibody-coated microvesicles engineered for targeted delivery.
  • Incorporation of thymidylate kinase (a suicide protein) into the microvesicles.
  • In vitro or in vivo testing of microvesicle delivery to prostate cancer cells.
  • Assessment of cancer cell viability and apoptosis following azidothymidine (AZT) administration.

Main Results:

  • Demonstration of successful targeted delivery of microvesicles to prostate cancer cells.
  • Evidence of thymidylate kinase expression within the targeted cancer cells.
  • Quantification of enhanced cancer cell death in response to AZT treatment compared to control groups.
  • Analysis of the mechanism of cell death induced by the combined therapy.

Conclusions:

  • Antibody-coated microvesicles represent a promising platform for targeted drug and protein delivery in prostate cancer therapy.
  • The co-delivery of thymidylate kinase and subsequent AZT treatment shows potential for potentiating cancer cell death.
  • This approach warrants further investigation as a novel molecular targeted therapy for prostate cancer.

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.2K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
74
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
83